Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

NCT05907759 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

NIH

Sponsor class

Conditions

Lymphoma, Primary Effusion

Interventions

DRUG: Daratumumab SC

Sponsor

National Cancer Institute (NCI)